• Vaccine Name: live attenuated Brucella abortus 2308 delta pgm vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009159
• Type: Live attenuated vaccine
• Status: Research
• Host Species for Licensed Use: Cattle
• Host Species as Laboratory Animal Model: BALB/c mice; HeLa cells
• Antigen: phosphoglucomutase (pgm) gene deletion
• Preparation: Live rough-phenotype mutant strain with inability to assemble complete O side chain in LPS. (Ugalde et al., 2003)
• Description: The deltapgm strain is a phosphoglucomutase gene deletion mutant of Brucella abortus S2308 that synthesizes an incomplete O antigen resulting in a rough lipopolysaccharide phenotype. It was developed to overcome disadvantages of the S19 vaccine such as virulence in humans and interference with immune screening. Efficacy: Vaccination with the deltapgm strain induced protection levels comparable to those induced by the S19 vaccine. Immune response: The vaccine generated a proliferative splenocyte response and a cytokine profile typical of a Th1 response; no specific anti-O-antigen antibody response was detected by fluorescence polarization assay. (Ugalde et al., 2003)

Mouse Response

• Host Strain: BALB/c
• Host cell type: HeLa
• Immune Response: The vaccine generated a proliferative splenocyte response and a cytokine profile typical of a Th1 response; no specific anti-O-antigen antibody response was detected by fluorescence polarization assay. (Ugalde et al., 2003)
• Efficacy: Vaccination with the deltapgm strain induced protection levels comparable to those induced by the S19 vaccine. (Ugalde et al., 2003)
• Description: Protection, splenocyte proliferative response, and cytokine production were analyzed in BALB/c mice; intracellular multiplication studied in HeLa cells. (Ugalde et al., 2003)